drugset / Trial / NCT07199764
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase II, open-label, single-arm study of CD40/Dectin-1 immunotherapy as maintenance treatment in patients with unresectable pancreatic ductal adenocarcinoma (PDA) who have not progressed following 4-8 months of first line (1L) chemotherapy.
Timeline
- Start
- 2025-11-25
- Primary completion
- 2027-10
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitazalimab | Monoclonal antibody | 0.9 mg/kg | Intravenous |
| Subject | Odetiglucan | Other / unclassified | 4 mg/kg | Intravenous |